Operator: And thank you. And our next question comes from Matt Larew from William Blair. Your line is now open.
Matt Larew: Hey, good afternoon and thanks for taking my questions. Sort of a two-parter on your partnership programs that numbers continue to progress, not to over 125 programs, the number in the clinic went from 15 to 16 and just by nature of the growth in the size of the programs, I guess I would have thought that might have moved up a bit more with €“ and has assumed that wouldn’t be an area where you see pipeline rationalization in terms of assets getting closer to the clinic. So was that just a function of timing? And then maybe the second part would be, within that $125 million programs signed into SPL at the end of the year. Are all of those actively progressing? And has that always been the case, or are there programs that are part of these partnerships that perhaps fit into this bucket of being paused or rationalized?
Doug Doerfler: So, to answer your €“ the first part of your question, there has been some in and out of the programs with our partners. We don’t get involved in that decision. Most of them are based on strategy or data. But there has been some people €“ programs dropping out and programs coming in. So, the net effect has been an increase in the number of programs in the clinics. And I think we said 16 right now. And that €“ those 16 would be directly affecting our ability to develop milestone payments and eventually commercial revenues for the company. So, it’s good that it’s going in that direction. Of the 125, we typically a deal, let’s say, a deal, let’s just assume for a minute, 10 programs for deal. Many of those had are actually named programs within a few other views, they could be a named target and that targeted an indication.
And some of the other programs would be unnamed what they would be within a general field of views. Some of them are being worked on pre-clinically in early-stage clinic. But a number of those I mentioned 125, we have got 15 in the clinic. So, 15 are in the clinic moving along and there is a more than a handful pre-clinically. And then there are some that are €“ they have options on. Does that answer your question, Matt?
Matt Larew: Yes, I think so. I was taken curious notes to go back and read them again, but I think that helps. Thank you.
Operator: Thank you. And one moment for our next question. And our next question comes from Jacob Johnson from Stephens. Your line is now open.
Jacob Johnson: Hey. Thanks. Good evening. Maybe, Doug, just circling back on the comments around process assemblies. It sounds like this was largely in cell therapy. Is this related to rationalization of programs or just lumpiness? And then maybe if you could just comment on kind of what’s assumed in the guide for FY €˜23 as it relates to the consumable side of things. Thanks.
Doug Doerfler: Jacob, let me €“ thanks for the question. Let me turn it over to Ron.
Ron Holtz: Yes. So, the pull-through generally has been quite consistent across many years. The key thing that’s happening last year is as a late-stage partner moves towards preparations for commercialization and into commercialization. As you would expect, their purchasing gets larger and that’s part of the long-term growth of a customer moving from clinical stage into commercial stage. And so the big picture is strong growth. Closer in, if you are looking on a quarterly basis, that’s quite lumpy. And so, we saw strong PAs early in the year, and that’s part of why we ended up with 50-50 split and lighter PA sales, particularly in the fourth quarter. And most of that is associated with a large customer, which is sort of a poster child for what can happen when you have those later-stage companies approaching commercialization.
Jacob Johnson: Okay. Got it. Thanks for that Ron.
